A phase II trial of gefitinib in patients with rising PSA following radical prostatectomy or radiotherapy

Authors

  • Greetta Joensuu Cancer Gene Therapy Group, Molecular Cancer Biology Program & Transplantation Laboratory & Haartman Institute & Finnish Institute for Molecular Medicine, University of Helsinki, Helsinki, Finland; International Comprehensive Cancer Center Docrates, Helsinki, Finland
  • Timo Joensuu International Comprehensive Cancer Center Docrates, Helsinki, Finland
  • Nina Nupponen Molecular Cancer Biology Program, University of Helsinki, Helsinki, Finland
  • Mirja Ruutu Department of Urology, Helsinki University Central Hospital, Helsinki, Finland
  • Juhani Collan Department of Oncology, Helsinki University Central Hospital, Helsinki, Finland
  • Sari Pesonen Cancer Gene Therapy Group, Molecular Cancer Biology Program & Transplantation Laboratory & Haartman Institute & Finnish Institute for Molecular Medicine, University of Helsinki, Helsinki, Finland; HUSLAB, Helsinki University Central Hospital, Helsinki, Finland
  • Akseli Hemminki Cancer Gene Therapy Group, Molecular Cancer Biology Program & Transplantation Laboratory & Haartman Institute & Finnish Institute for Molecular Medicine, University of Helsinki, Helsinki, Finland; HUSLAB, Helsinki University Central Hospital, Helsinki, Finland

DOI:

https://doi.org/10.3109/0284186X.2011.617387

Abstract

No abstract available

Downloads

Download data is not yet available.

Downloads

Additional Files

Published

2012-01-01

How to Cite

Joensuu, G., Joensuu, T., Nupponen, N., Ruutu, M., Collan, J., Pesonen, S., & Hemminki, A. (2012). A phase II trial of gefitinib in patients with rising PSA following radical prostatectomy or radiotherapy. Acta Oncologica, 51(1), 130–133. https://doi.org/10.3109/0284186X.2011.617387

Issue

Vol. 51 No. 1 (2012): Acta Oncologica

Section

Articles